RxDoctor Payments Data

Matthew Coombs, MD

Family Medicine · Monaca, PANPI 1972529725

Payments from drug & device makers

$12,880in general payments, 2019–2025

Across 742 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$977
  • Lilly USA, LLC$869
  • Pfizer$627
  • Amgen$502
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$12,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,880 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$54,073
Medicare patients
224
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin182$196,093
OzempicSemaglutide103$144,257
EliquisApixaban153$124,437
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$63,528
TrulicityDulaglutide36$46,668
JanuviaSitagliptin Phosphate42$40,405
VraylarCariprazine Hcl27$39,735
XareltoRivaroxaban33$28,874
LinzessLinaclotide32$27,686
FarxigaDapagliflozin Propanediol27$27,599
RybelsusSemaglutide21$23,091
EntrestoSacubitril/Valsartan12$22,670
Tresiba Flextouch U-200Insulin Degludec11$18,610
VascepaIcosapent Ethyl22$15,267
Breo ElliptaFluticasone/Vilanterol16$15,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$252$221,752207 claims
Novo NordiskOzempic, Rybelsus$2,113$167,347124 claims
PfizerEliquis$627$124,437153 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$977$85,239103 claims
AbbVieVraylar, Linzess, Synthroid$2,475$71,534132 claims
Lilly USA, LLCTrulicity$869$46,66836 claims
MerckJanuvia$258$40,40542 claims
Johnson & JohnsonXarelto$322$28,87433 claims
AstraZenecaFarxiga$384$27,59927 claims
NovartisEntresto$87$22,67012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$5,460524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Monaca

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →